Triad Wealth Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$282K Buy
1,978
+29
+1% +$4.4K 0.02% 446
2026
Q2
$300K Buy
1,949
+160
+9% +$24K 0.02% 446
2026
Q1
$273K Buy
+1,789
New +$274K 0.02% 411
2024
Q3
– Sell
-1,014
Closed -$108K – 615
2024
Q2
$108K Buy
+1,014
New +$102K 0.06% 147

Other funds holding NVS

Triad Wealth Partners's NVS Position: Q3 2026 in Review

Triad Wealth Partners increased its Novartis (NVS) stake by 1.5% in Q3 2026, buying an estimated $4.4K and bringing the position to 1,978 shares worth $282K. The position accounts for 0.02% of the portfolio, ranked #446.

Triad Wealth Partners first reported a position in NVS in Q2 2024 and has held it in 4 quarters since. The position peaked at $300K in Q2 2026. 1,561 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Triad Wealth Partners held 1,978 shares of Novartis worth $282K as of Q3 2026.
  • Triad Wealth Partners bought 29 Novartis shares in Q3 2026, an estimated $4.4K.
  • Novartis made up 0.02% of Triad Wealth Partners's portfolio in Q3 2026, its #446 holding.
  • Triad Wealth Partners first reported a position in Novartis in Q2 2024 and has held it in 4 quarters since.
  • Triad Wealth Partners's Novartis position peaked at $300K in Q2 2026.
  • 1,561 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Triad Wealth Partners's 13F filing for Q3 2026, filed 26 Oct 2026.